Newsfeeds - Spark Newswire

4 minute read

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank

Today, 2:09 PM

The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the company’s Silicon Valley Bank.

AMBA

1 minute read

News

Praxis Precision Says Co Has Aggregate Balance Of Less Than 20% Of Co’s Total Cash

By Benzinga Newsdesk

Today, 2:09 PM

-SEC Filing

PRAX

1 minute read

HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $16 Price Target

By Benzinga Newsdesk

Today, 2:09 PM

HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $16 price target.

PRAX

3 minute read

Dow Jumps Over 300 Points; S&P 500 Rises 1.5%

By Lisa Levin

Today, 2:09 PM

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Friday. The Dow traded up 1.03% to 33,343.73 while the NASDAQ rose 1.92% to 11,682.86. The S&P 500 also rose, gaining, 1.51% to 4,041.51.

ARDX

4 minute read

Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

Today, 2:09 PM

Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.

ADMP

3 minute read

Nasdaq Up 150 Points; Crude Oil Rises 1%

By Lisa Levin

Today, 2:09 PM

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Friday. The Dow traded up 0.59% to 33,197.08 while the NASDAQ rose 1.32% to 11,614.60. The S&P 500 also rose, gaining, 0.92% to 4,017.84.

ARDX

1 minute read

Despite Trial Failure Praxis Still Seeks Advancing Essential Tremor Program Into Phase 3 Study

By Vandana Singh

Today, 2:09 PM

Praxis Precision Medicines Inc (NASDAQ:PRAX) announced topline results from the Essential1 study evaluating the efficacy, safety, and tolerability of ulixacaltamide (PRAX-944)…

PRAX

1 minute read

Praxis Precision Medicines’s Essential1 Study Evaluating Ulixacaltamide (PRAX-944) For Essential Tremor Did Not Reach Statistical Significance On Primary Endpoint, Change From Baseline To Day 56 In The Modified Activities Of Daily Living (mADL) Score

By Benzinga Newsdesk

Today, 2:09 PM

Ulixacaltamide demonstrated improvement in modified Activities of Daily Living (mADL) primary efficacy endpoint relative to placebo that did not reach statistical significance (p=0.126), and achieved nominal

PRAX